Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

BACKGROUND: Imatinib shows limited efficacy in patients with gastrointestinal stromal tumors (GISTs) carrying secondary KIT mutations. HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinical trials for the treatment of T315I mutant chronic myelogenous leukemia (CML),...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuechao, Wang, Guangfeng, Yan, Xianglei, Qiu, Haibo, Min, Ping, Wu, Miaoyi, Tang, Chunyang, Zhang, Fei, Tang, Qiuqiong, Zhu, Saijie, Qiu, Miaozhen, Zhuang, Wei, Fang, Douglas D., Zhou, Zhiwei, Yang, Dajun, Zhai, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815454/
https://www.ncbi.nlm.nih.gov/pubmed/31673329
http://dx.doi.org/10.1186/s13578-019-0351-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815454/
https://www.ncbi.nlm.nih.gov/pubmed/31673329
http://dx.doi.org/10.1186/s13578-019-0351-6

Ejemplares similares